Bolt Biotherapeutics BOLT 深 沪
等待开盘 08-15 09:30:00 美东时间
5.44
-0.180
-3.20%
华盛通- 最 高5.705
- 今 开5.66
- 成交量 2.06万股
- 最 低 5.36
- 昨 收 5.62
- 总市值 1042.85万
- 52周最高 14.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.20
- 委 比 97.85%
- 总股本 191.70万
- 历史最高 861.40
- 量 比 2.03
- 振 幅 6.14%
- 历史最低 5.20
- 每 手 1
- 风险率 2.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bolt Metals Completes Debt Settlement to Enhance Financial Stability
Bolt Metals ( ($TSE:BOLT) ) has provided an update. Bolt Metals Corp. has compl...
08-06 09:35
福特科隆工厂与工会就裁员规定达成一致
（转自：欧洲并购与投资） 福特科隆工厂与工会就裁员规定达成一致 图片来源： DALL-E, IT BOLTWISE 德国科隆福特工厂的劳资双方就计划中...
07-14 16:05
Bolt Metals Completes Debt Settlement to Preserve Cash
Bolt Metals ( ($TSE:BOLT) ) has shared an update. Bolt Metals Corp. has success...
06-12 12:02
Bolt Metals Corp. Announces Strategic Debt Settlement
An update from Bolt Metals ( ($TSE:BOLT) ) is now available. Bolt Metals Corp. ...
06-04 13:33
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
Lake Street Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $4
Lake Street analyst Chad Messer initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $4.
05-20 22:36
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.36) by 19.44 percent. This is a 3.57 percent decrease over losses of $(0.28) per share
05-13 04:31
